Outlook Therapeutics (OTLK) Total Current Liabilities (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Total Current Liabilities of $38.9 million for Q1 2026, up 56.65% year-over-year from $24.8 million in Q1 2025, and down 20.74% quarter-over-quarter from $49.1 million in Q4 2025.
Outlook Therapeutics (OTLK) Total Current Liabilities (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Total Current Liabilities for 12 consecutive years, with $38.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 56.65% year-over-year to $38.9 million; the TTM figure through Mar 2026 stood at $38.9 million (up 56.65% YoY), while the FY2025 annual figure was $45.8 million, up 7.66% from the prior year.
- Total Current Liabilities retreated to $38.9 million in Q1 2026 per OTLK's latest filing, from $49.1 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $54.1 million in Q1 2024 and bottomed at $15.1 million in Q4 2022.
- Historically, Total Current Liabilities has averaged $38.1 million across 5 years, with a median of $42.6 million in 2024.
- Annual changes were most pronounced in 2023 — Total Current Liabilities jumped 204.8% — and 2025, when it plunged 54.1%.
- Outlook Therapeutics' Total Current Liabilities stood at $15.1 million in 2022, then surged by 204.8% to $46.0 million in 2023, then climbed by 4.93% to $48.2 million in 2024, then rose by 1.7% to $49.1 million in 2025, then decreased by 20.74% to $38.9 million in 2026.
- Business Quant data shows OTLK's Total Current Liabilities at $38.9 million in Q1 2026, $49.1 million in Q4 2025, and $45.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Outlook Therapeutics | 93.64 Mn | 82.40 Mn | -8,265.00 | 28.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.88 Mn |
| Dec 31, 2025 | 49.06 Mn |
| Sep 30, 2025 | 45.81 Mn |
| Jun 30, 2025 | 31.49 Mn |
| Mar 31, 2025 | 24.82 Mn |
| Dec 31, 2024 | 48.24 Mn |
| Sep 30, 2024 | 42.55 Mn |
| Jun 30, 2024 | 42.55 Mn |
| Mar 31, 2024 | 54.08 Mn |
| Dec 31, 2023 | 45.97 Mn |
| Sep 30, 2023 | 46.73 Mn |
| Jun 30, 2023 | 49.93 Mn |
| Mar 31, 2023 | 43.53 Mn |
| Dec 31, 2022 | 15.08 Mn |
| Sep 30, 2022 | 19.73 Mn |
| Jun 30, 2022 | 18.43 Mn |
| Mar 31, 2022 | 31.41 Mn |
| Dec 31, 2021 | 19.95 Mn |
| Sep 30, 2021 | 6.75 Mn |
| Jun 30, 2021 | 19.64 Mn |